X

Trial Profile

A Phase 1 Open Label Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Regadenoson (Primary)
Indications Reperfusion injury
Focus Adverse reactions

Most Recent Events

30 Apr 2022 Results assessing safety of regadenoson infusion during and after lung transplantation, presented at the 42nd Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
18 Feb 2020 Planned End Date changed from 1 Aug 2021 to 1 Aug 2022.
18 Feb 2020 Planned primary completion date changed from 1 Aug 2020 to 1 Aug 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com